Givosiran is an RNA interference (RNAi) therapeutic indicated for the treatment of adults with acute hepatic porphyria. As a small interfering RNA (siRNA) designed to target and degrade aminolevulinate… Read more
Givosiran is an RNA interference (RNAi) therapeutic indicated for the treatment of adults with acute hepatic porphyria. As a small interfering RNA (siRNA) designed to target and degrade aminolevulinate synthase 1 (ALAS1) mRNA in hepatocytes, this medication effectively reduces the hepatic production of neurotoxic heme intermediates such as aminolevulinic acid and porphobilinogen. To support rigorous pharmaceutical quality control, our catalogue includes high-quality reference standards for Givosiran. These compounds are essential for accurate impurity profiling, ensuring that any pharmacopeial or non-pharmacopeial impurities are identified and quantified throughout the development and manufacturing lifecycle. Laboratories also rely on our portfolio of stable isotope labelled compounds to facilitate precise bioanalytical testing and method validation. These analytical tools enable researchers to maintain stringent quality standards while monitoring the drug's efficacy and ensuring the safety of pharmaceutical formulations during every stage of analysis.